Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arepitant injection plus ondansetron vs ondansetron alone for prevention of chemotherapy-induced nausea and vomiting
ChiCTR2300073659Phase 4Recruiting
- Sponsor
- Dandong First Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aprepitant in cancer and chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Dandong First Hospital. Primary endpoint: Emetic relief rate. Started May 2023; status: recruiting.
02
Drugs
aprepitant
03
Conditions
cancerchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2300073659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073659.